Zepzelca（lurbinectedin 鲁比卡丁）

On June 15th, 2020, the US Food and Drug Administration (FDA) approved the marketing of small molecular cytotoxic drug Zepzelca(lurbinectedin Rubicardin) from Jazz Pharmaceuticals plc and PharmaMar Company for the treatment of adult patients with metastatic small cell lung cancer (SCLC) after platinum chemotherapy.
Zepzelca(lurbinectedin Ruby Cardin) _ Hong Kong Jimin Pharmaceutical

[Indications of Zepzelca(lurbinectedin Rubicardin) injection]
Zepzelca(lurbinectedin Rubicardin) can be used to treat adult patients with metastatic small cell lung cancer (SCLC) after platinum chemotherapy. The indication was approved under accelerated approval according to the overall remission rate and remission duration.

[dosage and administration method of Zepzelca(lurbinectedin]
1. Recommended dosage
The recommended dose of Zepzelca is 3.2 mg/m2 for intravenous infusion, and the infusion time should exceed 60 minutes. Once every 21 days until the disease progresses or unacceptable toxicity appears.
Only when the absolute neutrophil count (ANC) is at least 1,500 cells/mm ~ 3 and the platelet count is at least 100,000/mm ~ 3, can the treatment with Zepzelca be started.

[Zepzelca(lurbinectedin Rubicardin) injection is used in special population]
Pregnant women: Zepzelca may cause fetal injury. Use effective contraceptive measures during the treatment with Zepzelca and within 6 months after the last dose.
Breastfeeding: Women are advised not to breastfeed during the treatment with Zepzelca and for at least 2 weeks after the final dose.
Children: Safety and efficacy in pediatric patients have not been determined.

Note: If there is any new packaging for drugs, the new packaging shall prevail. The above information comes from the Internet or translated by student volunteers in medical colleges and universities (if there are any mistakes or omissions, please help me to correct them). It is for internal discussion of medical staff only, without any basis for medication. Please consult the attending physician for specific medication guidelines.